LivaNova PLC Reports Strong 2024 Financial Performance

LivaNova PLC ( (LIVN) ) has released its Q4 earnings. Here is a breakdown of the information LivaNova PLC presented to its investors.

LivaNova PLC is a global medical technology company specializing in innovative solutions for neurological and cardiac conditions, with a strong presence in over 100 countries. The company recently announced its fourth-quarter and full-year 2024 financial results, showcasing significant growth and strategic advancements.

In the fourth quarter of 2024, LivaNova reported a revenue of $321.8 million, marking a 3.8% increase on a reported basis and a 6.8% rise on an organic basis compared to the previous year. The full-year revenue reached $1.25 billion, reflecting an 8.7% growth on a reported basis and a 10.7% increase organically. The company also achieved a full-year GAAP diluted earnings per share of $1.16 and an adjusted diluted earnings per share of $3.38.

Key highlights include the successful completion of the OSPREY clinical study for obstructive sleep apnea and the publication of pivotal articles on treatment-resistant depression, demonstrating the efficacy of their VNS Therapy. Additionally, LivaNova appointed Natalia Kozmina as the Chief Human Resources Officer in January 2025.

Looking ahead, LivaNova projects a revenue growth of 5.0% to 6.0% on a constant-currency basis for 2025, with an expected adjusted diluted earnings per share ranging from $3.65 to $3.75. The company remains focused on innovation and operational excellence to sustain its growth trajectory.